As the presidential election nears -- with just 21 days to go -- questions are swirling about the candidates' health. Over ...

Strong Memorial Hospital, Highland Hospital and other UR Medicine sites paused elective surgeries indefinitely, beginning Oct ...

The annual Guthrie Gala raised over $363,000 to support Guthrie’s Emergency Medicine department. The gala was held on ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

A planned one-day work stoppage set for Tuesday by health care workers at the University of Michigan has been called off ...

With less than 12 hours before 2,700 Michigan Medicine hospital workers were scheduled to begin a one-day strike in Ann Arbor ...

智通财经APP获悉，9月30日，Prime Medicine(PRME.US)宣布与施贵宝(BMY.US)达成战略研发合作和授权协议，共同开发下一代T细胞疗法。这一合作将结合Prime ...

重复扩增疾病（RED）是一组异质性疾病，主要影响神经系统，包括脆性X综合征和遗传性共济失调等。这类疾病很常见，全球患病率约为1/3000。然而，由于临床表现各异、地理分布不均以及技术限制，患者数量可能被低估。

The 2024 Nobel Prize in Medicine was awarded Monday to two American scientists, Victor Ambros and Gary Ruvkun, for their ...

北京时间2024年10月11日00时49分，Editas Medicine, Inc.（EDIT.us）股票出现异动，股价急速下挫5.09%。截至发稿，该股报2.96美元/股，成交量128.566万股， 换手率 1.56%，振幅4.49%。

周五,BMO Capital对Prime Medicine (NASDAQ:PRME)保持乐观态度,重申"跑赢大市"评级,目标价为19.00美元。该公司强调,这家生物技术公司最近宣布威尔逊病(WD)为其第二个主要项目,但市场对此基本忽视。据该公司称,由于未满足的医疗需求高,而Prime Medicine有潜力解决当前研究中基因疗法的局限性,WD代表了一个重要机会。 该公司采用脂质纳米粒(LNP)递 ...

周五，Leerink Partners维持了对Editas Medicine（NASDAQ:EDIT）的"市场表现"评级，目标价保持在$8.00不变。这一决定是在Editas Medicine最近宣布与DRI Healthcare Trust达成融资协议之后做出的。根据协议条款，Editas将获得$5700万的预付款，以换取来自与VRTX现有许可协议的未来许可费和付款。 该协议授权DRI Heal ...